198 related articles for article (PubMed ID: 34816373)
1. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
[TBL] [Abstract][Full Text] [Related]
2. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H
BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
5. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A; Arenberger P; Balser S; Beissert S; Cauthen A; Czeloth N; Soung J; Jazayeri S; Weisenseel P; Jayadeva G
Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
[No Abstract] [Full Text] [Related]
6. A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu C; Zhang F; Ding Y; Li Y; Zhao Y; Gu J; Guo S; Pan W; Jin H; Sun Q; Kang X; Yang Q; Jiang X; Song Z; Lu Q; Pang X; Kuang Y; Deng D; Li Y; Zhang C; Tao J; Xie L; Wang Y; Wang J; Wang G
Int Immunopharmacol; 2022 Nov; 112():109248. PubMed ID: 36126411
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Interchangeability of AVT02 and Humira
Feldman SR; Kay R; Reznichenko N; Sobierska J; Dias R; Otto H; Haliduola HN; Sattar A; Ruffieux R; Stroissnig H; Berti F
BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
[TBL] [Abstract][Full Text] [Related]
9. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W;
BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555
[TBL] [Abstract][Full Text] [Related]
11. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
Menter A; Cohen S; Kay J; Strand V; Gottlieb A; Hanauer S; Eduru SK; Buschke S; Lang B; Liesenfeld KH; Schaible J; McCabe D
Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
[TBL] [Abstract][Full Text] [Related]
12. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
Samtsov AV; Bakulev AL; Khairutdinov VR; Kokhan MM; Korotaeva TV; Minullin IK; Vylegzhanina OA; Dubenskiy VV; Khalilov BV; Khotko AA; Zykova OS; Chumachenko IV; Lukyanov AM; Artemeva AV; Pukhtinskaia PP
PLoS One; 2022; 17(2):e0263214. PubMed ID: 35130291
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Papp KA; Lebwohl MG; Thaçi D; Jaworski J; Kwiek B; Trefler J; Dudek A; Szepietowski JC; Reznichenko N; Narbutt J; Baran W; Kolinek J; Daniluk S; Bartnicka-Maslowska K; Reich A; Andrashko Y; Kim S; Bae Y; Jeon D; Jung J; Lee H; Pyo T; Ko W
BioDrugs; 2024 Jan; 38(1):121-131. PubMed ID: 37991693
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
Li J; Xue Z; Wu Z; Bi L; Liu H; Wu L; Liu S; Huang X; Wang Y; Zhang Y; Qi W; He L; Dai L; Sun L; Li X; Shuai Z; Zhao Y; Wang Y; Xu J; Zhang H; Yu H; Chen X; Bao C
Clin Rheumatol; 2022 Oct; 41(10):3005-3016. PubMed ID: 35676450
[TBL] [Abstract][Full Text] [Related]
15. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Narbutt J; Philipp S; Spelman L; Weglowska J; Zhang N; Strober B
J Am Acad Dermatol; 2017 Jun; 76(6):1093-1102. PubMed ID: 28291552
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
BioDrugs; 2020 Jun; 34(3):381-393. PubMed ID: 32078145
[TBL] [Abstract][Full Text] [Related]
18. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
[TBL] [Abstract][Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
20. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
